医疗专业人员

下面列出了当前开展的临床试验。

根据地点、状态和其他条件对此研究列表进行过滤。

1. Gemini Study To Evaluate The Integration Of Cancer Genetic Testing Into A Cancer Clinical Practice At Mayo Clinic At Arizona

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the prevalence of genetic mutations in cancer patients from various ethnic populations seeking care at Mayo Clinic cancer clinics.

2. Treatment Resistant Depression Subcallosal Cingulate Network

   Rochester, Minn.

   The purpose of this study is to evaluate the effectiveness and safety of bilateral stimulation of the SCCwm using the Infinity DBS system as an adjunctive treatment of non-psychotic unipolar Major Depression Disorder (MDD) for adults who are experiencing an Major Depressive Episode (MDE) with inadequate response to 4 or more antidepressant treatments.

3. Blood-Brain Barrier Disruption (BBBD) For Liquid Biopsy In Subjects With GlioBlastoma Brain Tumors

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and effectiveness of using Exablate Model 4000 Type-2.0/2.1 in adults with Glioblastoma brain tumors to increase temporarily the permeability of the blood brain barrier, allowing increased passage of circulating free DNA (cfDNA) for sampling and analysis.

4. A Study Of Early-onset Alzheimer's Disease

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is designed to look at disease progression in individuals with early onset cognitive impairment . Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EO-nonAD) participants,and (3) cognitively normal (CN) control participants.

5. A Study to Analyze Intracerebral Hemorrhage Hematoma

   Jacksonville, Fla.

   The purpose of this study is to to take the usual waste material from the removal of hematoma and apply an array of -Omics approaches (including for example genomics, transcriptomics, lipidomics, proteomics, and metabolomics) to identify biomarkers that assess prognosis and identify key therapeutic targets.

6. Stem Cells from Skin Fibroblasts in Patients with Hereditary Peripheral Neuropathy

   Rochester, Minn.

   The purpose of this research is to develop stem cells from cells within patients’ skin in order to better understand peripheral neuropathy and help develop treatments.

7. Pituitary tumor registry

   Rochester, Minn.

   The purpose of this data registry involves the collection of standard of care clinical treatment regimens, diagnostic information and surgical outcomes which may include human specimens and associated genomewide expression data.  

8. Collection of Discarded Cerebrospinal Fluid for Research Purposes

   Rochester, Minn.

   The purpose of this study is to collect and store cerebrospinal fluid (CSF)from patients with normal CSF.  This stored CSF will be used in the future as a culture media to better understand how therapeutic cells delivered into the CSF will behave. 

9. Long Term Clinical Outcomes of Devic’s Disease

   Rochester, Minn., Jacksonville, Fla.

   Aims, purpose, or objectives:

   1. To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the latest revised criteria in 2015 by International Panel for Neuromyelitis Optica Diagnosis (IPND)
   2. To described the long term outcomes of a cohort of patients with a diagnosis of NMOSD
   3. To identify demographic, clinical and radiologic factors associated with long terms outcomes of NMOSD
   4. To determine if patients who are diagnosed with the revised 2015 IPND criteria, in particular those who do not satisfy previous criteria, are ultimately diagnosed with conditions other than NMOSD.
   5. To identify treatment effects and complications in this cohort of patients

10. Validation Of Early Prognostic Data For Recovery Outcome After Stroke For Future, Higher Yield Trials

    Rochester, Minn.

    VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.